International journal of dermatology · 2011
Successful treatment of Nocardia actinomycetoma with meropenem and amikacin combination therapy.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ameen Mahreen, Vargas Felipe, Arenas Roberto, del Mercado Elsa Vásquez
Аннотация
BACKGROUND: Actinomycetomas are chronic, granulomatous, subcutaneous infections caused by the traumatic inoculation of actinomycetes bacteria into the skin which produces nodular lesions with draining sinuses and discharging grains. Actinomycetomas can cause profound disability, and despite long-term chemotherapy, treatment failure is common.
AIMS: We investigated the efficacy of a novel drug regimen for the treatment of a severe case of Nocardia actinomycetoma of the leg.
MATERIAL AND METHODS: A 31-year-old man was treated with an initial three-week parenteral course of meropenem and amikacin combination therapy followed by long term oral sulphonamides.
RESULTS: Treatment was well-tolerated with no adverse effects, and there was complete clinical and microbiological cure with no recurrence.
CONCLUSION: Meropenem and amikacin combination therapy represents an important addition to the currently available treatments for actinomycetomas.
AIMS: We investigated the efficacy of a novel drug regimen for the treatment of a severe case of Nocardia actinomycetoma of the leg.
MATERIAL AND METHODS: A 31-year-old man was treated with an initial three-week parenteral course of meropenem and amikacin combination therapy followed by long term oral sulphonamides.
RESULTS: Treatment was well-tolerated with no adverse effects, and there was complete clinical and microbiological cure with no recurrence.
CONCLUSION: Meropenem and amikacin combination therapy represents an important addition to the currently available treatments for actinomycetomas.